Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature by Tenti, S et al.
Clinical Case Report Medicine®
OPENPrimary antiphospholipid syndrome during
aromatase inhibitors therapy
A case report and review of the literature
Sara Tenti, MDa, Nicola Giordano, MD, PhDb, Maurizio Cutolo, MD, PhDc, Fabio Giannini, MD, PhDd,
Antonella Fioravanti, MD, PhDa,
∗
Abstract
Rationale: Aromatase inhibitors (AIs) are a class of drugs widely used in the treatment of estrogen sensitive breast and ovarian
cancer which convert testosterone to estradiol and androstenedione to estrogen. The AIs of third generation, including anastrazole,
letrozole and exemestane, have actually become the standard of care of estrogen-receptor-positive breast cancer in menopausal
women and are recommended as adjuvant treatment after surgery in place of/or following tamoxifen. Their main side-effects include
reduction in bone mineral density, occurrence of menopausal manifestations and development of musculoskeletal symptoms which
are, usually, transient, but sometimes evolve into a typical form of arthritis, such as rheumatoid arthritis (RA). Recently, a pathogenic
linkage with other autoimmunity diseases, such as Sjogren syndrome (SjS), anti-synthetase antibody syndrome (ASAS), systemic
sclerosis (SS) and subacute cutaneous lupus erythematosus (SCLE), was also described.
Patient concerns: Here, we report the first case of a patient with primary antiphospholipid syndrome (APS) developed during
treatment with anastrazole.
Diagnosis: The patient developed a sudden onset of speech disturbance and disorientation, due to ischemic lesions, after
6 months of AIs therapy and the laboratory examination showed the positivity of anti-Cardiolipin antibodies, anti-b2 Glycoprotein
1 antibodies and Lupus Anticoagulant, so a certain diagnosis of APS was achieved.
Interventions: The patient was treated with warfarin associated to hydroxychloroquine and monthly cycles of low doses
intravenous immunoglobulins.
Outcomes:A good control of the disease was obtained despite the continuation of anastrazole; the patient’s clinical and laboratory
situation remained not modified after AIs withdrawal.
Lessons:We discussed the possible role of anastrazole treatment in inducing APS in our patient, reporting the available literature
data about the association between AIs treatment and autoimmune diseases. Furthermore, we analyzed the mechanism of action of
estrogens in the pathophysiology of autoimmune rheumatic disorders.
Abbreviations: aCL = anti-cardiolipin antibodies, ACTH = adrenocorticotropic hormone, aGP1 = anti-b2 Glycoprotein 1
antibodies, AIH = autoimmune hepatitis, AIMSS = aromatase inhibitors-induced musculoskeletal symptoms, AIs = aromatase
inhibitors, ANA = anti-nuclear antibodies, anti-CCP = anti-cyclic citrullinated peptide antibodies, aPL = antiphospholipid antibodies,
APS = antiphospholipid syndrome, APTT = prolonged activated partial thromboplastin time, ASAS = anti-synthetase antibody
syndrome, BMD = bone mineral density, CK = creatine kinase, CRP = C reactive protein, CT = computed tomoghraphy, DHEAS =
dehydroepiandrosterone sulfate, DLE = discoid lupus erythematosus, E2 = estradiol, ENA = extractable nuclear antigens, ESR =
erythrocyte sedimentation rate, INR = International normalized ratio, LAC = lupus anticoagulant, LMWH = low molecular weight
heparin, MCA = middle cerebral artery, MCF = metacarpophalangeal, MRI = magnetic resonance imaging, PIP = proximal
interphalangeal, PT = prothrombin time, RA = rheumatoid arthritis, RF = rheumatoid factor, SCLE = subacute cutaneous lupus
erythematosus, SjS=Sjogren syndrome, SLE= systemic lupus erythematosus, SpA= spondyloarthropaty, SS= systemic sclerosis.
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Aromatase inhibitors (AIs) are a class of drugs widely used in the
events;[25,26] so, tamoxifen was switched to anastrazole (1mg/treatment of estrogen sensitive breast and ovarian cancer. Their
mechanism of action consists in inhibiting the aromatase enzyme
which is responsible for the conversion of testosterone to estradiol
and androstenedione to estrogen.[1] The AIs of third generation,
including anastrazole, letrozole and exemestane, have actually
become the standard of care of estrogen-receptor-positive breast
cancer in menopausal women and are recommended as adjuvant
treatment after surgery in place of/or following tamoxifen,
considered for decades the cornerstone of endocrine therapy in this
field.[2] AIs insure more efficacy and induce less life-threatening
adverse events than tamoxifen.[3]Themain side-effects ofAIs therapy
include reduction in bone mineral density (BMD), occurrence of
menopausal manifestations and development of musculoskeletal
symptoms, such as arthralgia, morning stiffness, tenosynovitis,
trigger finger, and carpal tunnel syndrome.[4,5] Joint pain is usually
transient and tends to disappear after therapy discontinuation, but
growingevidencehasdemonstrated thatAIs cansometimes induceor
exacerbate a typical arthritis, as rheumatoid arthritis (RA)[6–10] or
some subsets of spondyloarthropaty (SpA).[11] A pathogenic linkage
between treatment with AIs and other autoimmunity diseases, such
as Sjogren syndrome (SjS), anti-synthetase antibody syndrome
(ASAS), systemic sclerosis (SS) and subacute cutaneous lupus
erythematosus (SCLE), was also reported.[12–19] AIs reduce the
synthesis of estrogens, which are known to affect the immune
response, exerting opposite immunostimolant or immunodepressive
effects, according to the dose and the duration of exposure.[20–23]
Furthermore, the increase of aromatase activity in normal tissue
occurs during aging and is responsible for the production of themain
amount of peripheral estrogens which modulate the immune
reactivity and cell proliferation.[22]
Here, we describe the first case of antiphospholipid syndrome
(APS), a systemic autoimmune disease defined by the occurrence
of venous and arterial thromboses and recurrent fetal losses, in
the presence of antiphospholipid antibodies (aPL), which
developed during treatment with anastrazole.[24]
2. Case presentation
In October 2012, a 56 years old female patient was admitted to
the Neurology Unit for sudden onset of speech disturbance and
disorientation. She had a history of right breast cancer (ductal
carcinoma estrogen-receptor positive; T1N0M0) diagnosed in
March 2010 and treated with upper-outer quadrantectomy and
adjuvant radiotherapy in the months of August and September
2010. At the end of the radiotherapy cycle, she received treatment
with tamoxifen (20mg/day). In February 2012, she experienced a
superficial venous thrombophlebitis of the left femoral vein; at
this time, the patient was not taking any pharmacological
therapy, including glucocorticoids, except for tamoxifen. Labo-
ratory analysis showed an increase of D-dimer (1.2ng/ml, range
<500ng/ml), fibrinogen (590mg/dl, range 200–400) and C
reactive protein (CRP) (1.2mg/dl, vn <0.5mg/dl), while the
thrombophilia tests, including protein C, protein S, antithrombin
III, homocysteine resulted within normal limits. Furthermore, the
aPL, anti-Cardiolipin antibodies (aCL), anti-b2 Glycoprotein 1
antibodies (aGP1), Lupus Anticoagulant (LAC) and anti-nuclear
antibodies (ANA), were negative. The thrombophlebitis was
managed with low molecular weight heparin (LMWH) (fonda-
parinux 7,5mg/day tapered to 2,5mg/day in June 2012),
switched to ticlopidine 500mg/day amonth later. The occurrence
of thrombophlebitis was supposed to be due to tamoxifen,2
considering the known risk of this drug of inducing thrombotic
day). In August 2012, after 6 months of anastrazole therapy,
despite the ticlopidine treatment, she developed a transient motor
aphasia and she was admitted to Stroke Unit. Brain magnetic
resonance imaging (MRI) showed multiple lacunar infarcts.
Unfortunately, no evaluation for autoimmunity or thrombophilia
markers was performed. Anticoagulant therapy with warfarin
was introduced during the hospitalization. In September 2012,
she went to the emergency department complaining of a band-
like abdominal pain; a computed tomoghraphy (CT) scan of the
abdomen showed the enlargement of left adrenal gland with
evidence of recent haemorrage. Warfarin was stopped and
LMWH treatment (enoxaparin 6000UI/day) was started.
InOctober 2012, shewasfirst time referred to theNeurologyUnit.
At the admission, shewas not oriented to person, place, and time and
she spoke hesitantly and non-fluently (motor aphasia). Neurological
examinationalso showedmoderate right facial and limbhemi-paresis
andno sensorydeficit. Thebloodpressurewas severely reduced (max
value 55mmHg) while cardiac examination was normal. The neck
and skin examinations were normal, showing no lymphadenopathy,
malar rash, acrocyanosis, or livedo reticularis. No significant
abnormalities were found during lung auscultation; the abdomen
was soft, not-tender, andnot-distendedwithnohepatosplenomegaly.
No signs of edema or thrombosis were pointed out.
Laboratory examinations revealed mild thrombocytopenia
(120,000/mmc, range 150,000–400,000), mild erythrocyte
sedimentation rate (ESR) increase (47mm/h, range 0–35mm/
h), D-dimer and fibrinogen elevation, prolonged activated partial
thromboplastin time (APTT) and normal prothrombin time (PT),
International normalized ratio (INR), CRP, thrombophilia
screening, kidney and liver function, hemoglobin, electrolytes,
glycemia, immunoglobulins, C3, C4 complement factors and
urinalysis (Table 1). Consistently with a sub-acute adrenal
insufficiency, basal serum concentrations of cortisol were reduced
and adrenocorticotropic hormone (ACTH) increased. The serum
levels of dehydroepiandrosterone sulfate (DHEAS), testosterone
and androstenedione resulted extremely low, while the concen-
trations of estradiol (E2), progesterone and 17-OH progesterone
were within normal range according to the age of the patient
(Table 1). Immunological tests showed positive ANA, (1:640,
homogeneous pattern), high titer of aCL antibodies IgG and IgM
(94.3GPLU/ml, range <10; 16.4MPLU/ml, range <7, respec-
tively), aGP1 antibodies IgG, IgM and IgA (81.3U/ml, range <5;
18.1U/ml, range <5; 28.2U/ml, range <5, respectively). The test
for the detection of LAC was positive, as well as antiphospha-
tydilserine antibodies IgG and IgM (106GPLU/ml, range <10;
18MPLU/ml, range <10). Anti-dsDNA, extractable nuclear
antigens (ENA), anti-cyclic citrullinated peptide antibodies (anti-
CCP) and rheumatoid factor (RF) were negative.
The brain Diffusion-Weighted MRI revealed lesions with
restricted diffusion in the left occipital and temporo-parietal lobe,
and in the left insular cortex not detectable in the previous
examination and consistent with subacute ischemia. The brain
CT- angiography showed occlusion of the first tract of left-sided
middle cerebral artery (MCA1). The other performed instrumen-
tal examinations (chest radiography, abdomen ultrasonography,
electrocardiogram, echocardiogram, arterial and venous lower
limbDoppler ultrasonography) did not show anything significant
except for a mild-moderate mitral insufficiency.
Considering the multiple episodes of cerebral ischemia and the
high titer positivity of all aPL subtypes, a diagnosis of primary
APS, according to the 2006 updated criteria,[24] was made.
Table 1
Coagulation tests and endocrine screening results in the patient
described in the text at the time of admission at Neurology Unit.
Laboratory data Patient’s results Normal range
D-dimer 2.13mg/l, <0.5mg/l
Fibrinogen 422mg/dl 150–350mg/dl
PT 11.5 s 9–12 s
INR 1.06 0.85–1.19
APTT 100 s 26–35 s
Coagulation factor II 121% 70–130%
Coagulation factor VII 101% 70–130%
Coagulation factor XII 78% 70–140%
Antithrombin III activity 98% 80–120%
Protein C – functional 114% 70–140%
Protein S– functional 87% 75–125%
Resistance to activated protein C (ratio) 1.5 >0.85
Factor V Leiden mutation Negative Negative
Homocysteine 11.3mm/l <13mm/l
PAI-1 activity 13.3ng/ml 4–43ng/ml
Prothrombin gene mutation Negative Negative








17-OH Progesteron 0.01ng/ml 0.13–0.51ng/ml
ACTH=adrenocorticotropic hormone, APTT= activated partial thromboplastin time, DHEA-S=
dehydroepiandrosterone sulfate, INR= International normalized ratio, MTHFR=methylenetetrahy-
drofolate reductase, PAI=plasminogen activator inhibitor, PT=Prothrombin time.
Tenti et al. Medicine (2019) 98:13 www.md-journal.comThe patient was treated with enoxaparin 6000 UI for 2 times a
day and then a bridging therapy with warfarin was introduced
until the achievement of an optimal INR value (3–4). Further-
more, she started a replacement treatment for adrenal insuffi-
ciency with hydrocortone acetate (intravenous flebocortid at the
dosage of 50mg every 6 hours for 48 hours), followed by oral
cortone acetate at the dosage of 25mg at 8 hours and of 6.5 mg at
13 hours and at 18 hours. Before the discharge, a cycle of
intravenous human immunoglobulins (Flebogamma) at a dosage
of 400mg/kg/day for 5 consecutive days was administered and
hydroxychloroquine (400mg/day) was added.
Considering the high risk of cancer recurrence when AIs
therapy lasts less than 5 years, the patient continued anastrazole
therapy.[27] As the time of writing, the patient is still on therapy
with warfarin, hydroxychloroquine (400mg/day) and monthly
cycles of low-dose intravenous immunoglobulins (400mg/kg/day
in a single monthly infusion), according to the dose protocol
previously experienced in systemic lupus erythematosus (SLE),
discoid lupus erythematosus (DLE) and primary and secondary
APS.[28–30] Her clinical conditions appeared stable over time and
no more ischemic or thrombotic events occurred. The patient
discontinued anastrazole after the recommended 5 years without
any changes in her clinical history.
Informed consent was obtained from the patient for publica-
tion of this case report.3. Discussion and review of the literature
We presented the case of a patient with primary APS occurred
after 6 months of anastrazole treatment. The diagnosis was made
after recurrent episodes of cerebral ischemia and the detection of3
a triple positivity for aPL (LAC+ aCL antibodies+ aGP1
antibodies). We think that the APS occurred and has been
caused by 6 months of anastrazole treatment. Conversely, one
could argue that the onset of APS following AIs therapy is just
coincidence rather than a causal relationship.
It is actually known that one of themajor side effects associated
to AIs therapy is represented by arthralgias.[31–33] Although being
usually mild or moderate, these musculoskeletal symptoms may
cause an important impact on quality of life and significantly
reduce the compliance to the AIs therapy.[34] The first description
of the frequent occurrence of arthralgia during AIs therapy came
back to 2001, when Donnellan et al[35] reported that the 16% of
77 patients treated with AIs for breast cancer developed joint
pain. Subsequently, more studies explored the frequency of
musculoskeletal complaints during AIs therapy, observing a
much higher prevalence (about 40%).[36,37] Furthermore, the
term AIs-induced musculoskeletal symptoms (AIMSS) has been
introduced to indicate the association of arthralgia, symmetric
morning stiffness which improves with activity, a feeling of
abrupt aging and soft tissue thickening.[31,32] The incidence of
AIMSS in woman treated with AIs widely varies from 5% to
47%, due to the lacking of formal diagnostic criteria for this
syndrome.[37] The exact mechanism responsible for AIMSS is not
fully understood, but a major role is played by estrogens
deprivation.[38] Indeed, it was demonstrated that estrogens have
anti-nociceptive and pain modulating properties.[39]
More recently, a pathogenic linkage between AIs therapy and
well established autoimmune diseases has been hypothesized.
We conducted a search of the literature concerning clinical
reports on the development of autoimmune diseases during AIs
therapy in September 2018 (the period examined was September
2007–August 2018). The strategy to select the literature data
consisted in a detailed search in scientific databases PubMed,
Scopus, Cochrane Library and EMBASE. A MEDLINE search
was conducted using the MeSH terms “aromatase inhibitors”,
“anastrazole”, “letrozole”, “exemestane” in combination with
“autoimmune diseases" "autoimmunity" and “rheumatological
disorders”. Studies were considered eligible if they met the
following criteria:1. patients with a diagnosis of autoimmune and rheumatic
diseases,
therapy with anastrazole, letrozole or exemestane,2.
3. studies published from 2007 to the present, totally written in
English language.
The studies which were excluded from the review were the
following:1. those analyzing the effects of AIs therapy on the development
of musculoskeletal symptoms, as arthralgia, not conclusive for
the diagnosis of autoimmune rheumatic diseases,
review articles,2.
3. anti-estrogen drugs other than AIs.In total, 46 potential studies were found; no additional papers
were found by hand searching of references. Of these, 2 were
excluded because they were written in a language other than
English. Based on the title and the abstract content, 21 of these
articles were not included in our review. The full texts of the
remaining 23 studies were read, and a further 7 studies were
excluded, because the patients analyzed were not diagnosed with
autoimmune rheumatic diseases. Finally, we identified 16
assessable articles reporting the development of rheumatic
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Tenti et al. Medicine (2019) 98:13 www.md-journal.comFour reports showed a potential association between AIs and
RA (Table 2).[6–9] The first paper was published in 2007 and
described the case of a woman with a history of advanced right
breast cancer treated with exemestane who developed, after few
days from the beginning of the therapy, joint pain of her hips,
shoulders, knees, wrists and hands associated to prolonged
morning stiffness. After 4 weeks, she presented a symmetric and
active arthritis with wrists, metacarpophalangeal (MCF) and
proximal interphalangeal (PIP) swellings which did not improve
after exemestane discontinuation. ESR and CRP resulted
increased and hands radiographs and MRI showed typical
erosions, so the diagnosis of RA was made.[6] Another similar
report was described by Bruzzese et al.[7] Also in this case, after 1
year from the starting of anastrazole, the patient firstly
experienced widespread arthralgias evolving 3 years later in
high activity RA with positivity of RF and anti-CCP. In the same
year, Bertolini et al[8] presented 3 cases of RA occurred after AIs
therapy (anastrazole in 1 patient and letrozole followed by
exemestane in the other 2 patients). The symptoms characterized
mainly by hands arthralgias developed after few weeks from the
AIs initiation, while the diagnosis of RA was obtained after a
mean period of 33 months. A correlation between AIs therapy
and cutaneous nodulosis, a particular RAmanifestation, was also
reported. Indeed, a woman with a pre-existent long-standing RA,
who took letrozole for breast cancer, developed, after 16 months,
multiple small subcutaneous nodules on the fingers of both hands
diagnosed as "accelerated cutaneous nodulosis". After the drug
discontinuation, a slow decrease in size and tenderness of the
nodules was observed.[9]
Not only RA, but also other definite types of arthritis in the
field of SpA, were found to be associated to AIs treatment
(Table 2). Indeed, Scarpa et al[11] carefully evaluated 18 post-
menopausal women in treatment with AIs for breast cancer and,
according to the European Spondyloarhropathy StudyGroup,[40]
diagnosed 10 subjects with undifferentiated spondyloarhrop-
athy, 2 with oligoarthritis and simple arthralgia the other 6
patients.
Interestingly, Laroche et al[12] referred 24 women treated with
AIs and experiencing pain greater than 5/10 on a visual analog
scale, to rheumatologic consultation to find out if any established
condition could cause these complaints (Table 2). Apart from 5
patients with osteoarthritis, shoulder tendinitis or paraneoplastic
aponeurositis, Authors classified 10 patients as having sicca
syndrome of the eyes and mouth, of whom 7 with probable SjS
and 1 definite SjS, according to San Diego criteria.[41] Further-
more, the number of patients with autoantibodies resulted higher
than they expected. A relationship between AIs and SjS was
suggested also in a more recent case-series study which describes
the development of primary SjS, according to the 2002 European
criteria,[42] in 3 women during the first year of adjuvant therapy
(anastrazole in 2 patients and letrozole in 1 patient) for breast
cancer (Table 2).[13] These findings confirm the protective role of
estrogens against apoptosis of the exocrine secretory glands,
previously suggested.[43] Others presented the case of a patient
who developed SjS with neuropathy of both legs, after
anastrazole therapy for breast cancer (Table 2). The Authors,
after excluding other possible causes of neuropathy, such as
chemotherapy side effects, paraneoplastic manifestation or
cryoglobulinemia-related vasculitis, concluded that there was a
causal relationship between AIs and SjS.[14]
Also a case of ASAS, after treatment with AIs, in a patient with
a previous diagnosis of RA was described (Table 2).[15] The
woman developed dyspnea related to a severe bilateral interstitial5
lung disease and necrotizing myopathy associated to a creatine
kinase (CK) increase and positivity of anti-Jo1 and antiRo52
antibodies, after 3 months of therapy with letrozole. After the
drug withdrawal and the establishment of immunosuppressive
treatment, the myositis and the interstitial disease significantly
improved, but a re-exacerbation was reported, after the
introduction of a second AIs agent (anastrazole). The temporal
correlation between AIs administration and the onset of the
clinical manifestations and the rapid recurrence induced by the
resume of the therapy, strongly supported an etiological
association between these drugs and ASAS.
Among the wide range of connective tissue disorders, also SS,
in a very early phase, has been described as associated to AIs
therapy (Table 2). However, in this case the patient started to
present hand joint pain and stiffness after two years of letrozole
therapy and 2 years later was diagnosed as having early SS;
letrozole was switched to exemestane and an improvement of the
articular pain was noted.[16]
Particularly interesting are the reports of SCLE induced by AIs,
because the role of estrogens in lupus disease activity have been
the subject of debate for many years (Table 2).[17–19] Indeed,
opposite to what observed during AIs treatment, reports in
women with lupus showed an increase of disease flares due to
estrogen-containing hormone replacement therapy and animal
model studies demonstrated a significant clinical improvement of
SLE, after anti-estrogen therapy.[44,45]
Finally, there are some reports supporting the hypothesis of a
role of AIs in triggering also autoimmune hepatitis (AIH),
probably affecting immune regulation.[46–48]
In the current case, it seems that the APS is not occurred by
chance, since the AIs therapy have induced some pathogenetic
changes of the immune system which persisted over time, also
after anastrazole discontinuation. There are several factors
known to trigger the development of thrombosis in APS including
infection, malignancies, trauma, surgery, withdrawal of oral
anticoagulation and drugs.[49,50] At this regard, several pharma-
cological agents, including anti-epileptic, anti-hypertensive, anti-
arrhythmic drugs and antibiotics, have been linked to the
occurrence of aPL antibodies, especially LA and rarely to the
development of clinical manifestations of APS.[51] More recently,
the detection of aPL antibodies was demonstrated also to be
associated to immunotherapy (interferon-a and Interleukin-2)
and tumor necrosis factor inhibitors.[52] It was hypothesized that
drugs could insult cell membranes leading to the formation of
neo-antigens or increasing the density of antigens bound to the
cell surface; alternately, they could induce the production of
circulating antibodies.[52] Although such evidence, there are no
previous published data about estrogens antagonists and APS. It
was actually demonstrated that estrogens play a pivotal role in
the pathophysiology of autoimmune rheumatic diseases, consid-
ering for instance the prevalence of such disorders in female
gender or their ability to influence the diseases flares.[22]
However, various in vitro and in vivo studies showed that the
estrogens may exert opposite functions on immune system,
as inhibiting T cell autoimmunity and stimulating antibodies
production from B cells. These multifaced effects of estrogens on
autoimmunity could depend on their different concentrations, on
the phase of the disease in which they act and on ability to
generate various types of metabolites which are effectively active
hormones.[53,54] The blockade of aromatase, the key enzyme for
the conversion of androgens to estrogens, has been associated to
the development of a wide range of autoimmune diseases, as
described above. It has been suggested that estrogens may play an
[9] Chao J, Parker BA, Zvaifler NJ. Accelerated cutaneous nodulosis
Tenti et al. Medicine (2019) 98:13 Medicineanti-inflammatory, protective role before the autoimmunity
occurrence, while AIs, reducing the estrogens levels, could acts
as triggering factors.[54] At this regard, some Authors investigated
the involvement of aromatase blockade in the development of SjS.
They used female aromatase gene knockout (ArK0) mice as a
model of estrogen deficiency, observing that ArK0mice presented
SjS-like autoimmune lesions in lacrimal and salivary glands, due
to B-cell proliferation and production of autoantibodies.
Furthermore, they reported a significant amount of adiposity
of the ArK0 mice salivary glands with an increased number of
macrophages and consequent cytokines production, compared to
wild typemice. Finally, the autoimmune lesions were exacerbated
by administration of an AI, hypothesizing a key role of estrogens
deficiency in the pathogenesis of autoimmunity.[55]
Actually, the role of AIs in APS remains totally unexplored,
despite a correlation between the estradiol serum levels with aCL
antibodies and ischemic attacks was previously reported.[56]
Our case report and review of the literature highlight that AIs
therapy for breast cancer can trigger the onset of autoimmune
changes resulting in various rheumatic diseases, which persisted
over time, such as APS. These considerations may be useful in the
clinical practice, because we think it should be very important to
screen the patients starting AIs therapy for rheumatological
remarks. However, the pathogenetic mechanism behind the
development of APS, after AIs treatment, still remains unex-
plored. So preclinical studies are needed to investigate the
pathophysiology of APS induced by this class of drugs and large
clinical studies are mandatory to confirm our experience.Author contributions
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